Jason Carstens

Part of Pluristyx, Inc., panCELLa, Inc. is a privately held early-stage biotechnology firm based in Toronto, CA. panCELLa was acquired by Pluristyx, Inc. on October 06, 2022. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive failsafe™ and cloaked cells™/iact cells. The Canadian company continues its internal R & D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination, and tolerization. The company was founded in 2015 by Armand Keating and Andras Nagy, and has created platforms that allow for the development of safe, universal, cost-effective, “ off-the-shelf ” therapeutic cell products for medicine.

Part of Pluristyx, Inc., panCELLa, Inc. is a privately held early-stage biotechnology firm based in Toronto, CA. panCELLa was acquired by Pluristyx, Inc. on October 06, 2022. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive failsafe™ and cloaked cells™/iact cells. The Canadian company continues its internal R & D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination, and tolerization. The company was founded in 2015 by Armand Keating and Andras Nagy, and has created platforms that allow for the development of safe, universal, cost-effective, “ off-the-shelf ” therapeutic cell products for medicine.

Pluristyx, Inc. is a privately held biotechnology company that helps industry and academic researchers solve manufacturing and analytical challenges in cryopreservation, drug development, regenerative medicine, and cell and gene therapy. The company is based in Seattle, WA and has subsidiaries in United States and Canada. The company has decades of experience supporting every stage of cell therapy product development, from cell banking to drug product manufacturing including analytical testing and release of clinical grade cell therapy products. Pluristyx offers consulting, wet-lab services, and pluripotent stem cell products to support novel therapeutic developers. The company was founded in 2018 by Kaye Reiter, Benjamin Fryer, Jason Carstens. Benjamin Fryer has been the CEO since 2018.

Pluristyx, Inc. is a privately held biotechnology company that helps industry and academic researchers solve manufacturing and analytical challenges in cryopreservation, drug development, regenerative medicine, and cell and gene therapy. The company is based in Seattle, WA and has subsidiaries in United States and Canada. The company has decades of experience supporting every stage of cell therapy product development, from cell banking to drug product manufacturing including analytical testing and release of clinical grade cell therapy products. Pluristyx offers consulting, wet-lab services, and pluripotent stem cell products to support novel therapeutic developers. The company was founded in 2018 by Kaye Reiter, Benjamin Fryer, Jason Carstens. Benjamin Fryer has been the CEO since 2018.

Part of Pluristyx, Inc., panCELLa, Inc. is a privately held early-stage biotechnology firm based in Toronto, CA. panCELLa was acquired by Pluristyx, Inc. on October 06, 2022. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive failsafe™ and cloaked cells™/iact cells. The Canadian company continues its internal R & D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination, and tolerization. The company was founded in 2015 by Armand Keating and Andras Nagy, and has created platforms that allow for the development of safe, universal, cost-effective, “ off-the-shelf ” therapeutic cell products for medicine.